Decreased Tc-99m sestamibi uptake in a sternal brown tumor indicating response to anti metabolic therapy for secondary hyperparathyroidism

ÖZKAN E., Arslan N., Arslanoglu A., Karacalioglu A. O.

CLINICAL NUCLEAR MEDICINE, cilt.32, sa.8, ss.661-662, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Editöre Mektup
  • Cilt numarası: 32 Sayı: 8
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1097/rlu.0b013e3180a1acde
  • Dergi Adı: CLINICAL NUCLEAR MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.661-662
  • Anahtar Kelimeler: hyperparathyroidism, brown tumor, Tc-99m sestamibi, vitamin D therapy
  • Ankara Üniversitesi Adresli: Evet

Özet

Brown tumors are rare but serious complications of renal osteodystrophy, and can be treated by parathyroidectomy or by pharmacological treatment of hyperparathyroidism. In addition to parathyroid lesions such as adenoma, hyperplasia, and carcinoma, brown tumors have been detected effectively by using dual phase Tc-99m sestamibi and T1-201 chloride. We describe an unusual case of brown tun tor at the manibrium sterni which shows marked increased Tc-99m sestamibi uptake on the initial scan, with decreasing tracer activity on follow-up scan indicating a response to antimetabolic therapy.